|
US20040081653A1
(en)
*
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
|
US7480593B2
(en)
*
|
2005-08-03 |
2009-01-20 |
Suresh Gopalan |
Methods and systems for high confidence utilization of datasets
|
|
ES2625259T3
(es)
|
2006-08-29 |
2017-07-19 |
Oxford Biotherapeutics Ltd |
Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AU2009331528A1
(en)
*
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
|
US20120077269A1
(en)
|
2008-12-30 |
2012-03-29 |
Cellartis Ab |
Use of a protein in stem cell and cancer applications
|
|
BRPI1009232B1
(pt)
|
2009-03-05 |
2022-05-03 |
E.R. Squibb & Sons, Llc. |
Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1
|
|
EP2374816B1
(en)
*
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
|
WO2011124635A1
(en)
*
|
2010-04-07 |
2011-10-13 |
Humalys |
Binding molecules against chikungunya virus and uses thereof
|
|
EP2575880B1
(en)
*
|
2010-05-27 |
2019-01-16 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
WO2012009568A2
(en)
|
2010-07-16 |
2012-01-19 |
Adimab, Llc |
Antibody libraries
|
|
CN103476429B
(zh)
*
|
2010-09-03 |
2016-08-24 |
施特姆森特克斯股份有限公司 |
新型调节剂及使用方法
|
|
WO2012031280A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
|
US9778264B2
(en)
|
2010-09-03 |
2017-10-03 |
Abbvie Stemcentrx Llc |
Identification and enrichment of cell subpopulations
|
|
AU2015234335B2
(en)
*
|
2010-09-29 |
2017-09-28 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
US8637642B2
(en)
|
2010-09-29 |
2014-01-28 |
Seattle Genetics, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
JP5980202B2
(ja)
*
|
2011-05-09 |
2016-08-31 |
株式会社ペルセウスプロテオミクス |
トランスフェリン受容体を特異的に認識できる抗体
|
|
JP6371222B2
(ja)
|
2011-12-05 |
2018-08-08 |
トレリス バイオサイエンス リミテッド ライアビリティー カンパニー |
インフルエンザの受動免疫用抗体
|
|
ES2886123T3
(es)
*
|
2012-01-31 |
2021-12-16 |
Regeneron Pharma |
Anticuerpos anti-asic1 y usos de los mismos
|
|
JP5939855B2
(ja)
*
|
2012-03-23 |
2016-06-22 |
国立大学法人 宮崎大学 |
トランスフェリン受容体抗体
|
|
WO2013192594A2
(en)
*
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind c-met
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CA2893794C
(en)
|
2012-11-08 |
2021-11-09 |
University Of Miyazaki |
Antibody capable of specifically recognizing transferrin receptor
|
|
US10570199B2
(en)
|
2012-11-21 |
2020-02-25 |
Km Biologics Co., Ltd. |
Human antibody against IL-18
|
|
EP3003373A4
(en)
|
2013-03-14 |
2016-10-19 |
Contrafect Corp |
COMPOSITION AND METHODS BASED ON INTRANASALLY RELEASED NEUTRALIZING ANTIBODIES FOR IMPROVED THERAPEUTIC EFFECTIVENESS
|
|
US9475874B2
(en)
|
2013-08-26 |
2016-10-25 |
MabVax Therapeutics, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
|
WO2015034052A1
(ja)
|
2013-09-05 |
2015-03-12 |
国立大学法人 宮崎大学 |
ヒトインテグリンａ６ｂ４と特異的に反応する抗体
|
|
US10081681B2
(en)
|
2013-09-20 |
2018-09-25 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
RU2720282C1
(ru)
|
2014-02-04 |
2020-04-28 |
Контрафект Корпорейшн |
Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
|
|
US10639370B2
(en)
|
2014-02-04 |
2020-05-05 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
US20170173005A1
(en)
|
2014-03-27 |
2017-06-22 |
Research Foundation Of The City University Of New York |
Method for detecting or treating triple negative breast cancer
|
|
KR102401595B1
(ko)
*
|
2014-05-09 |
2022-05-24 |
삼성전자주식회사 |
항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
|
|
US9975960B2
(en)
*
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
PT3204417T
(pt)
|
2014-10-10 |
2020-10-08 |
Innate Pharma |
Bloqueio de cd73
|
|
US9938356B2
(en)
|
2014-11-10 |
2018-04-10 |
Medimmune Limited |
Binding molecules specific for CD73 and uses thereof
|
|
HRP20201756T8
(hr)
|
2014-11-21 |
2021-08-20 |
Bristol-Myers Squibb Company |
Antitijela koja sadrže modificirane regije teškog lanca
|
|
DK3221363T3
(da)
|
2014-11-21 |
2020-08-10 |
Bristol Myers Squibb Co |
Antistoffer mod cd73 og anvendelser deraf
|
|
BR112017011170A2
(pt)
|
2014-12-18 |
2018-02-27 |
Hoffmann La Roche |
método para determinar a citotoxicidade dependente do complemento de uma composição
|
|
EP3259288A1
(en)
*
|
2015-02-20 |
2017-12-27 |
Innate Pharma |
Cd73 blockade
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
AU2016257929B2
(en)
|
2015-05-04 |
2022-10-20 |
Cytomx Therapeutics, Inc |
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
|
|
WO2016208755A1
(ja)
*
|
2015-06-25 |
2016-12-29 |
株式会社カネカ |
液体注入方法
|
|
CN108351287B
(zh)
*
|
2015-07-15 |
2019-08-09 |
贝克顿迪金森公司 |
用于调整细胞仪测量的系统和方法
|
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
|
US10793636B2
(en)
|
2016-07-11 |
2020-10-06 |
Corvus Pharmaceuticals, Inc. |
Anti-CD73 antibodies
|
|
BR112019000544A2
(pt)
|
2016-07-15 |
2019-04-24 |
Takeda Pharmaceutical Company Limited |
métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
|
|
AU2017307610B2
(en)
|
2016-08-04 |
2023-10-05 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
|
US10617720B2
(en)
*
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
EP3548515A1
(en)
|
2016-12-01 |
2019-10-09 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
|
|
EP3556773A4
(en)
*
|
2016-12-13 |
2020-08-19 |
Astellas Pharma Inc. |
HUMAN ANTI-CD73 ANTIBODY
|
|
PT3383916T
(pt)
|
2017-01-24 |
2022-03-30 |
I Mab Biopharma Us Ltd |
Anticorpos anti-cd73 e seus usos
|
|
HUE065242T2
(hu)
|
2017-05-30 |
2024-05-28 |
Bristol Myers Squibb Co |
LAG-3-pozitív tumorok kezelése
|
|
BR112019021847A2
(pt)
|
2017-05-30 |
2020-06-02 |
Bristol-Myers Squibb Company |
Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US11220544B2
(en)
|
2017-07-14 |
2022-01-11 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies and uses thereof
|
|
AU2019208102B2
(en)
|
2018-01-12 |
2025-10-09 |
Takeda Pharmaceutical Company Limited |
Subcutaneous dosing of anti-CD38 antibodies
|
|
MA52422A
(fr)
|
2018-02-27 |
2021-01-06 |
Incyte Corp |
Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
|
|
KR102804816B1
(ko)
|
2018-03-09 |
2025-05-09 |
페인스 테라퓨틱스 인코포레이티드 |
항-cd73 항체 및 이의 용도
|
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
MA53097A
(fr)
|
2018-07-05 |
2021-05-12 |
Incyte Corp |
Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
|
|
WO2020020307A1
(en)
|
2018-07-25 |
2020-01-30 |
I-Mab Biopharma Co., Ltd. |
Anti-cd73 anti-pd-l1 bispecific antibodies
|
|
AU2019392090A1
(en)
|
2018-12-03 |
2021-06-17 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
KR102063341B1
(ko)
*
|
2018-12-31 |
2020-01-07 |
다이노나(주) |
Icam-1에 특이적으로 결합하는 항체 및 그의 용도
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020204977A1
(en)
*
|
2019-03-29 |
2020-10-08 |
Lankenau Institute For Medical Research |
Anti-nmda receptor antibodies and methods of use
|
|
AU2020346886A1
(en)
*
|
2019-09-13 |
2022-04-14 |
Memorial Hospital For Cancer And Allied Diseases |
Anti-CD371 antibodies and uses thereof
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
PE20221282A1
(es)
*
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
|
MX2022007573A
(es)
|
2020-01-03 |
2022-09-23 |
Incyte Corp |
Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b.
|
|
TWI873265B
(zh)
|
2020-01-03 |
2025-02-21 |
美商英塞特公司 |
抗ｃｄ７３抗體及其用途
|
|
WO2021142276A1
(en)
*
|
2020-01-12 |
2021-07-15 |
Vanderbilt University |
Human antibodies to rift valley fever virus
|
|
CN111738980B
(zh)
*
|
2020-05-14 |
2023-08-04 |
北京深睿博联科技有限责任公司 |
一种医学影像的显示方法、计算机设备及存储介质
|
|
WO2021241729A1
(ja)
*
|
2020-05-29 |
2021-12-02 |
ブライトパス・バイオ株式会社 |
抗ｃｄ７３抗体およびその用途
|
|
MX2023007850A
(es)
|
2020-12-29 |
2023-09-11 |
Incyte Corp |
Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
|
|
KR102887692B1
(ko)
*
|
2021-05-21 |
2025-11-18 |
주식회사 지놈앤컴퍼니 |
항-bcam 항체 또는 그의 항원 결합 단편
|
|
EP4351644A4
(en)
*
|
2021-06-08 |
2025-04-30 |
Merck Patent GmbH |
CD80 AND/OR CD86 BINDING PROTEINS AND OX40L
|
|
US20240425606A1
(en)
|
2021-08-30 |
2024-12-26 |
Lassen Therapeutics 1, Inc. |
Anti-il-11ra antibodies
|
|
CN114137231B
(zh)
*
|
2022-01-29 |
2022-04-29 |
北京大有天弘科技有限公司 |
一种血型不规则抗体的检测试剂盒及其应用
|
|
US12187806B2
(en)
|
2022-03-04 |
2025-01-07 |
Development Center For Biotechnology |
Anti-CD73 antibodies and use thereof
|
|
EP4572772A1
(en)
|
2022-08-17 |
2025-06-25 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024215624A2
(en)
*
|
2023-04-13 |
2024-10-17 |
A & G Pharmaceutical, Inc. |
Antibodies and conjugates against prostaglandin f2 receptor inhibitor and uses thereof
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|